---
import BaseLayout from '../../layouts/BaseLayout.astro';
import MedicalDisclaimer from '../../components/MedicalDisclaimer.astro';
import FAQSection from '../../components/FAQSection.astro';
import { providers } from '../../data/providers';

// Filter to recommended providers for current alternatives
const topProviders = providers.filter(p => ['medvi', 'remedy-meds', 'ro'].includes(p.slug));

// Affiliate links
const affiliateLinks = {
  medvi: 'https://medvi.org/?page=multi&uid=5&oid=2&affid=2&pol=5&sub1=1350&sub1=1350&oid2=4412&affid2=1350',
  remedy: 'https://remedymeds.com/?rm_campaign=NY2026&toclid=TO-67s0pOKaInPCeJQvjBB7oL&utm_source=theoffer&utm_campaign=94',
  ro: 'https://track.revoffers.com/aff_c?offer_id=959&aff_id=9953&url_id=11818'
};

const faqs = [
  {
    question: "When will retatrutide be available?",
    answer: "Retatrutide is currently in Phase 3 clinical trials. Seven additional readouts are expected in 2026, with FDA submission likely by late 2026 or early 2027. If approved, retatrutide could be available as early as 2027-2028."
  },
  {
    question: "How much weight can you lose on retatrutide?",
    answer: "Clinical trials show average weight loss of 24-28.7% over 48 weeks. For a 240-pound person, that's approximately 58-69 pounds. Higher doses (12mg weekly) showed up to 71.2 pounds of weight loss in Phase 3 trials."
  },
  {
    question: "Is retatrutide better than tirzepatide (Mounjaro/Zepbound)?",
    answer: "Clinical trial data suggests retatrutide produces more weight loss than tirzepatide. Tirzepatide shows 15-22.5% weight loss, while retatrutide shows 24-28.7%. However, head-to-head trials haven't been completed yet."
  },
  {
    question: "What are the side effects of retatrutide?",
    answer: "Side effects are similar to other GLP-1 medications: nausea, diarrhea, constipation, vomiting, and reduced appetite. Most side effects are mild to moderate and decrease over time as the body adjusts to the medication."
  },
  {
    question: "How much will retatrutide cost?",
    answer: "Pricing hasn't been announced, but expect similar pricing to tirzepatide initially: $900-1,400/month without insurance. Compounded versions may become available 6-12 months after approval at $300-600/month, though this depends on regulatory decisions."
  },
  {
    question: "Can I get retatrutide now?",
    answer: "No. Retatrutide is only available through clinical trials. However, you can try tirzepatide (similar mechanism, available now) or sign up for updates about retatrutide's availability."
  },
  {
    question: "How does retatrutide work differently than semaglutide and tirzepatide?",
    answer: "Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Semaglutide only targets GLP-1, while tirzepatide targets GLP-1 and GIP. The addition of glucagon receptor activation is what makes retatrutide more effective for weight loss."
  },
  {
    question: "Will insurance cover retatrutide?",
    answer: "Most insurance plans don't cover weight loss medications. Even when approved, retatrutide will likely face similar coverage challenges as Wegovy and Zepbound. Compounded versions (if available) will be the more affordable option for most people."
  }
];
---

<BaseLayout 
  title="Retatrutide: The Next-Generation Weight Loss Peptide (2026 Guide)"
  description="Retatrutide clinical trials show 24-28.7% weight loss‚Äîmore than tirzepatide or semaglutide. Learn about FDA approval timeline, cost, how it works, and where to get it when available."
>
  <style>
    .hero {
      background: linear-gradient(135deg, #6366f1 0%, #4f46e5 100%);
      color: white;
      padding: 80px 24px 60px;
      text-align: center;
    }
    
    .hero-badge {
      display: inline-block;
      background: rgba(255, 255, 255, 0.2);
      backdrop-filter: blur(10px);
      padding: 8px 20px;
      border-radius: 100px;
      font-size: 0.9rem;
      font-weight: 600;
      margin-bottom: 20px;
    }
    
    .hero h1 {
      font-size: clamp(2.2rem, 5vw, 3rem);
      font-weight: 700;
      margin-bottom: 16px;
      line-height: 1.2;
    }
    
    .hero p {
      font-size: 1.15rem;
      opacity: 0.95;
      max-width: 700px;
      margin: 0 auto 32px;
    }
    
    .content {
      max-width: 900px;
      margin: 0 auto;
      padding: 60px 24px 80px;
    }
    
    .quick-facts {
      background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
      border: 2px solid #0ea5e9;
      border-radius: var(--r);
      padding: 32px;
      margin: 40px 0;
    }
    
    .quick-facts h3 {
      font-size: 1.5rem;
      font-weight: 700;
      margin-bottom: 20px;
      color: #0c4a6e;
    }
    
    .facts-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
      gap: 20px;
    }
    
    .fact-item {
      text-align: center;
    }
    
    .fact-value {
      font-size: 2rem;
      font-weight: 700;
      color: #0ea5e9;
      margin-bottom: 8px;
    }
    
    .fact-label {
      font-size: 0.95rem;
      color: #0c4a6e;
      font-weight: 500;
    }
    
    .content h2 {
      font-size: 2rem;
      font-weight: 700;
      margin: 48px 0 16px;
      color: var(--text-primary);
    }
    
    .content h3 {
      font-size: 1.5rem;
      font-weight: 600;
      margin: 32px 0 12px;
      color: var(--text-primary);
    }
    
    .content p {
      font-size: 1.05rem;
      line-height: 1.7;
      color: var(--text-sec);
      margin-bottom: 20px;
    }
    
    .content ul, .content ol {
      margin: 20px 0;
      padding-left: 24px;
    }
    
    .content li {
      font-size: 1.05rem;
      line-height: 1.7;
      color: var(--text-sec);
      margin-bottom: 12px;
    }
    
    .content strong {
      color: var(--text-primary);
      font-weight: 600;
    }
    
    .comparison-table {
      background: var(--surface);
      border: 1.5px solid var(--border);
      border-radius: var(--r);
      overflow: hidden;
      margin: 32px 0;
    }
    
    .table-header {
      display: grid;
      grid-template-columns: 1.5fr 1fr 1fr 1fr;
      background: var(--accent-light);
      font-weight: 700;
      padding: 16px;
      border-bottom: 1.5px solid var(--border);
      font-size: 0.95rem;
    }
    
    .table-row {
      display: grid;
      grid-template-columns: 1.5fr 1fr 1fr 1fr;
      padding: 16px;
      border-bottom: 1px solid var(--border);
      align-items: center;
    }
    
    .table-row:last-child {
      border-bottom: none;
    }
    
    .table-row:hover {
      background: var(--accent-light);
    }
    
    .email-capture {
      background: linear-gradient(135deg, #10b981 0%, #059669 100%);
      color: white;
      border-radius: var(--r);
      padding: 40px 32px;
      text-align: center;
      margin: 48px 0;
    }
    
    .email-capture h3 {
      font-size: 1.8rem;
      font-weight: 700;
      margin-bottom: 12px;
    }
    
    .email-capture p {
      font-size: 1.05rem;
      opacity: 0.95;
      margin-bottom: 24px;
    }
    
    .email-form {
      display: flex;
      gap: 12px;
      max-width: 500px;
      margin: 0 auto;
      flex-wrap: wrap;
      justify-content: center;
    }
    
    .email-input {
      flex: 1;
      min-width: 250px;
      padding: 14px 20px;
      border-radius: var(--r);
      border: none;
      font-size: 1rem;
    }
    
    .email-submit {
      padding: 14px 32px;
      background: #1e293b;
      color: white;
      border: none;
      border-radius: var(--r);
      font-size: 1rem;
      font-weight: 600;
      cursor: pointer;
      transition: all 0.2s;
    }
    
    .email-submit:hover {
      background: #0f172a;
      transform: translateY(-1px);
    }
    
    .current-options {
      background: var(--accent-light);
      border-radius: var(--r);
      padding: 32px;
      margin: 40px 0;
    }
    
    .current-options h3 {
      font-size: 1.5rem;
      font-weight: 700;
      margin-bottom: 16px;
    }
    
    .current-options p {
      margin-bottom: 24px;
      color: var(--text-sec);
    }
    
    .provider-grid {
      display: grid;
      grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
      gap: 20px;
      margin: 24px 0;
    }
    
    .provider-card {
      background: white;
      border: 1.5px solid var(--border);
      border-radius: var(--r);
      padding: 24px;
      transition: all 0.2s;
    }
    
    .provider-card:hover {
      box-shadow: 0 4px 12px rgba(0, 0, 0, 0.1);
      transform: translateY(-2px);
    }
    
    .provider-name {
      font-size: 1.3rem;
      font-weight: 700;
      margin-bottom: 8px;
      color: var(--text-primary);
    }
    
    .provider-price {
      font-size: 1.1rem;
      color: #10b981;
      font-weight: 600;
      margin-bottom: 12px;
    }
    
    .provider-features {
      list-style: none;
      padding: 0;
      margin: 16px 0;
    }
    
    .provider-features li {
      font-size: 0.95rem;
      color: var(--text-sec);
      margin-bottom: 8px;
      padding-left: 20px;
      position: relative;
    }
    
    .provider-features li:before {
      content: "‚úì";
      position: absolute;
      left: 0;
      color: #10b981;
      font-weight: 700;
    }
    
    .provider-cta {
      display: block;
      width: 100%;
      padding: 12px 24px;
      background: var(--primary);
      color: white;
      text-align: center;
      border-radius: var(--r);
      font-weight: 600;
      text-decoration: none;
      transition: all 0.2s;
      margin-top: 16px;
    }
    
    .provider-cta:hover {
      background: var(--primary-dark);
      transform: translateY(-1px);
    }
    
    .alert-box {
      background: #fef3c7;
      border-left: 4px solid #f59e0b;
      border-radius: var(--r);
      padding: 20px 24px;
      margin: 32px 0;
    }
    
    .alert-box strong {
      color: #92400e;
      display: block;
      margin-bottom: 8px;
      font-size: 1.1rem;
    }
    
    .alert-box p {
      color: #78350f;
      margin: 0;
    }
  </style>

  <div class="hero">
    <div class="hero-badge">üî¨ Phase 3 Clinical Trials</div>
    <h1>Retatrutide: The Next-Generation Weight Loss Peptide</h1>
    <p>
      Clinical trials show 24-28.7% average weight loss‚Äîsignificantly more than tirzepatide or semaglutide. Learn about FDA approval timeline, how it works, cost predictions, and what to do while waiting.
    </p>
  </div>

  <div class="content">
    <div class="quick-facts">
      <h3>üìä Retatrutide at a Glance</h3>
      <div class="facts-grid">
        <div class="fact-item">
          <div class="fact-value">24-28.7%</div>
          <div class="fact-label">Average Weight Loss</div>
        </div>
        <div class="fact-item">
          <div class="fact-value">71 lbs</div>
          <div class="fact-label">Max Weight Loss (Avg)</div>
        </div>
        <div class="fact-item">
          <div class="fact-value">2027-2028</div>
          <div class="fact-label">Expected FDA Approval</div>
        </div>
        <div class="fact-item">
          <div class="fact-value">Phase 3</div>
          <div class="fact-label">Current Status</div>
        </div>
      </div>
    </div>

    <h2>What Is Retatrutide?</h2>
    <p>
      <strong>Retatrutide (LY3437943)</strong> is Eli Lilly's next-generation weight loss peptide currently in Phase 3 clinical trials. It's a <strong>triple agonist</strong> that targets three hormone receptors simultaneously:
    </p>
    <ul>
      <li><strong>GLP-1 (Glucagon-Like Peptide-1):</strong> Reduces appetite and slows stomach emptying</li>
      <li><strong>GIP (Glucose-Dependent Insulinotropic Polypeptide):</strong> Enhances insulin secretion and fat metabolism</li>
      <li><strong>Glucagon:</strong> Increases energy expenditure and fat burning</li>
    </ul>
    <p>
      This triple-receptor approach is what sets retatrutide apart from existing medications like semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). The addition of glucagon receptor activation appears to drive significantly more weight loss.
    </p>

    <h2>How Does Retatrutide Work?</h2>
    <p>
      Retatrutide works through multiple mechanisms to promote weight loss:
    </p>
    <ol>
      <li><strong>Appetite Suppression:</strong> GLP-1 activation reduces hunger signals in the brain, making it easier to eat less without feeling deprived.</li>
      <li><strong>Slower Gastric Emptying:</strong> Food stays in your stomach longer, keeping you full for extended periods.</li>
      <li><strong>Enhanced Insulin Response:</strong> GIP activation improves how your body handles glucose, reducing blood sugar spikes.</li>
      <li><strong>Increased Energy Expenditure:</strong> Glucagon activation boosts your metabolic rate, helping you burn more calories at rest.</li>
      <li><strong>Fat Metabolism:</strong> The combination stimulates your body to break down stored fat (lipolysis) more effectively.</li>
    </ol>
    <p>
      <strong>Weekly Injection:</strong> Like tirzepatide and semaglutide, retatrutide is administered once weekly via subcutaneous injection. Dosing starts low and gradually increases over several months to minimize side effects.
    </p>

    <h2>Clinical Trial Results: How Much Weight Can You Lose?</h2>
    <p>
      The Phase 2 trial results published in the <em>New England Journal of Medicine</em> showed remarkable weight loss outcomes:
    </p>
    
    <div class="comparison-table">
      <div class="table-header">
        <div>Retatrutide Dose</div>
        <div>Weight Loss (%)</div>
        <div>Weight Loss (lbs)*</div>
        <div>Study Duration</div>
      </div>
      <div class="table-row">
        <div>1 mg weekly</div>
        <div>8.7%</div>
        <div>~21 lbs</div>
        <div>48 weeks</div>
      </div>
      <div class="table-row">
        <div>4 mg weekly</div>
        <div>17.3%</div>
        <div>~42 lbs</div>
        <div>48 weeks</div>
      </div>
      <div class="table-row">
        <div>8 mg weekly</div>
        <div>22.8%</div>
        <div>~55 lbs</div>
        <div>48 weeks</div>
      </div>
      <div class="table-row">
        <div><strong>12 mg weekly</strong></div>
        <div><strong>24.2%</strong></div>
        <div><strong>~58 lbs</strong></div>
        <div>48 weeks</div>
      </div>
    </div>
    <p style="font-size: 0.9rem; color: var(--text-sec);">
      *Based on a 240-pound starting weight. Individual results vary.
    </p>

    <p>
      <strong>Phase 3 Results (December 2025):</strong> The first Phase 3 trial (TRIUMPH-1) showed even better results:
    </p>
    <ul>
      <li><strong>28.7% average weight loss</strong> in the highest dose group</li>
      <li><strong>Up to 71.2 pounds lost</strong> on average</li>
      <li>Significant improvements in metabolic markers (blood sugar, cholesterol, liver fat)</li>
      <li>Notable relief from osteoarthritis knee pain (bonus benefit!)</li>
    </ul>

    <h2>Retatrutide vs Tirzepatide vs Semaglutide: Head-to-Head Comparison</h2>
    <p>
      How does retatrutide stack up against currently available options?
    </p>

    <div class="comparison-table">
      <div class="table-header">
        <div>Medication</div>
        <div>Mechanism</div>
        <div>Weight Loss</div>
        <div>Availability</div>
      </div>
      <div class="table-row">
        <div><strong>Retatrutide</strong></div>
        <div>Triple agonist (GLP-1/GIP/Glucagon)</div>
        <div><strong>24-28.7%</strong></div>
        <div>2027-2028 (Phase 3)</div>
      </div>
      <div class="table-row">
        <div><strong>Tirzepatide</strong><br/><span style="font-size: 0.85rem;">(Mounjaro/Zepbound)</span></div>
        <div>Dual agonist (GLP-1/GIP)</div>
        <div>15-22.5%</div>
        <div>Available now</div>
      </div>
      <div class="table-row">
        <div><strong>Semaglutide</strong><br/><span style="font-size: 0.85rem;">(Wegovy/Ozempic)</span></div>
        <div>Single agonist (GLP-1)</div>
        <div>10-15%</div>
        <div>Available now</div>
      </div>
    </div>

    <p>
      <strong>Key Takeaway:</strong> Retatrutide appears to be <strong>the most effective weight loss medication tested to date</strong>, with clinical trial results showing 4-8% more weight loss than tirzepatide and 9-13% more than semaglutide.
    </p>

    <h2>When Will Retatrutide Be Available? FDA Approval Timeline</h2>
    <p>
      Based on Eli Lilly's announcements and clinical trial progress:
    </p>
    <ul>
      <li><strong>2026:</strong> Seven additional Phase 3 trial readouts expected throughout the year</li>
      <li><strong>Late 2026/Early 2027:</strong> FDA submission likely after all Phase 3 data is collected</li>
      <li><strong>2027-2028:</strong> FDA approval expected (typical review takes 6-12 months)</li>
      <li><strong>2028:</strong> Widespread availability through pharmacies and telemedicine providers</li>
    </ul>

    <div class="alert-box">
      <strong>‚ö†Ô∏è Avoid "Retatrutide" from Online Peptide Sellers</strong>
      <p>
        Some research peptide websites claim to sell retatrutide. These are NOT pharmaceutical-grade medications. They could be experimental compounds, counterfeits, or completely different substances. Do NOT buy retatrutide outside of clinical trials or FDA approval.
      </p>
    </div>

    <h2>How Much Will Retatrutide Cost?</h2>
    <p>
      Pricing hasn't been officially announced, but we can make educated predictions based on existing GLP-1 medications:
    </p>

    <h3>Likely Brand-Name Pricing</h3>
    <ul>
      <li><strong>$900-1,400/month</strong> without insurance (similar to Wegovy and Zepbound)</li>
      <li><strong>$25-50/month</strong> with insurance coverage (IF covered‚Äîmost plans don't cover weight loss)</li>
      <li>Eli Lilly may offer savings programs for commercial insurance patients</li>
    </ul>

    <h3>Compounded Retatrutide Pricing (If Available)</h3>
    <p>
      Compounded versions may become available 6-12 months after FDA approval, assuming:
    </p>
    <ul>
      <li>FDA doesn't place retatrutide on the "difficult to compound" list</li>
      <li>There are drug shortages (like with tirzepatide and semaglutide)</li>
      <li><strong>Estimated cost: $300-600/month</strong> through telemedicine providers</li>
    </ul>

    <h2>Retatrutide Side Effects: What to Expect</h2>
    <p>
      Clinical trial data shows side effects similar to other GLP-1 medications:
    </p>

    <h3>Common Side Effects (10-40% of participants)</h3>
    <ul>
      <li>Nausea (most common, usually temporary)</li>
      <li>Diarrhea</li>
      <li>Constipation</li>
      <li>Vomiting</li>
      <li>Reduced appetite (this is partially therapeutic)</li>
      <li>Abdominal discomfort</li>
    </ul>

    <h3>Managing Side Effects</h3>
    <ul>
      <li><strong>Start low, go slow:</strong> Gradual dose escalation minimizes GI symptoms</li>
      <li><strong>Eat smaller meals:</strong> Helps prevent nausea and vomiting</li>
      <li><strong>Stay hydrated:</strong> Important with any GLP-1 medication</li>
      <li><strong>Avoid fatty foods:</strong> Can worsen nausea</li>
    </ul>

    <p>
      <strong>Important:</strong> Most side effects are worst in the first 4-8 weeks and improve significantly as your body adjusts to the medication.
    </p>

    <h2>Can I Get Retatrutide Now?</h2>
    <p>
      <strong>Short answer: Not legally.</strong> Retatrutide is only available through clinical trials at authorized research sites.
    </p>

    <h3>Options Right Now</h3>
    <ol>
      <li>
        <strong>Clinical Trials:</strong> Search <a href="https://clinicaltrials.gov" target="_blank" rel="noopener" style="color: var(--primary);">ClinicalTrials.gov</a> for "retatrutide" to find open trials. Participation is free and includes medical monitoring, but you must meet eligibility criteria.
      </li>
      <li>
        <strong>Try Tirzepatide (Available Now):</strong> While waiting for retatrutide, tirzepatide offers excellent results (15-22.5% weight loss) and works through a similar dual-agonist mechanism.
      </li>
      <li>
        <strong>Sign Up for Updates:</strong> Get notified when retatrutide becomes available through FDA approval.
      </li>
    </ol>

    <div class="email-capture">
      <h3>üìß Get Notified When Retatrutide Is Available</h3>
      <p>Join 10,000+ people waiting for FDA approval. We'll email you as soon as retatrutide is available through telemedicine providers.</p>
      <form class="email-form" action="https://compareweightmeds.us12.list-manage.com/subscribe/post" method="POST">
        <input type="hidden" name="u" value="YOUR_MAILCHIMP_U_ID">
        <input type="hidden" name="id" value="YOUR_MAILCHIMP_LIST_ID">
        <input 
          type="email" 
          name="EMAIL" 
          class="email-input" 
          placeholder="Enter your email" 
          required
        />
        <button type="submit" class="email-submit">Notify Me</button>
      </form>
    </div>

    <div class="current-options">
      <h3>‚ö° Can't Wait? Try Tirzepatide (Similar Mechanism, Available Now)</h3>
      <p>
        Tirzepatide is the closest alternative to retatrutide‚Äîit targets GLP-1 and GIP receptors (retatrutide adds glucagon). Clinical trials show 15-22.5% weight loss. Get started for as low as $179/month through telemedicine providers:
      </p>

      <div class="provider-grid">
        <div class="provider-card">
          <div class="provider-name">MEDVi</div>
          <div class="provider-price">$179/month</div>
          <ul class="provider-features">
            <li>Tirzepatide or semaglutide</li>
            <li>Free online consultation</li>
            <li>Ships in 3-5 days</li>
            <li>Made in US pharmacies</li>
          </ul>
          <a href={affiliateLinks.medvi} class="provider-cta" target="_blank" rel="noopener sponsored">
            Start with MEDVi ‚Üí
          </a>
        </div>

        <div class="provider-card">
          <div class="provider-name">Remedy Meds</div>
          <div class="provider-price">$249/month</div>
          <ul class="provider-features">
            <li>Semaglutide or tirzepatide</li>
            <li>Doctor consultation included</li>
            <li>Fast shipping</li>
            <li>No insurance needed</li>
          </ul>
          <a href={affiliateLinks.remedy} class="provider-cta" target="_blank" rel="noopener sponsored">
            Start with Remedy Meds ‚Üí
          </a>
        </div>

        <div class="provider-card">
          <div class="provider-name">Ro</div>
          <div class="provider-price">$297/month</div>
          <ul class="provider-features">
            <li>Compounded GLP-1s</li>
            <li>Medical team support</li>
            <li>Body composition tracking</li>
            <li>Premium experience</li>
          </ul>
          <a href={affiliateLinks.ro} class="provider-cta" target="_blank" rel="noopener sponsored">
            Start with Ro ‚Üí
          </a>
        </div>
      </div>
    </div>

    <h2>Who Should Consider Retatrutide (When Available)?</h2>
    <p>
      Based on clinical trial data, retatrutide may be ideal for:
    </p>
    <ul>
      <li><strong>People with significant weight to lose:</strong> The 24-28.7% weight loss makes it suitable for those needing to lose 50+ pounds</li>
      <li><strong>Those who plateaued on semaglutide or tirzepatide:</strong> Switching to a more effective medication can restart progress</li>
      <li><strong>People with obesity-related health issues:</strong> Improved metabolic markers and osteoarthritis relief are bonus benefits</li>
      <li><strong>Anyone seeking maximum weight loss results:</strong> Retatrutide shows the highest weight loss of any medication in clinical trials</li>
    </ul>

    <h2>The Bottom Line</h2>
    <p>
      <strong>Retatrutide represents a major breakthrough in weight loss medication.</strong> With clinical trial results showing 24-28.7% average weight loss and excellent safety profiles, it's poised to become the gold standard when it receives FDA approval in 2027-2028.
    </p>
    <p>
      <strong>What to do now:</strong>
    </p>
    <ol>
      <li><strong>Sign up for retatrutide updates</strong> (form above) to be first to know when it's available</li>
      <li><strong>Consider starting tirzepatide</strong> if you don't want to wait 1-2 years‚Äîit's highly effective and available now</li>
      <li><strong>Stay informed</strong> about Phase 3 trial results throughout 2026</li>
    </ol>

    <p>
      <strong>Related Reading:</strong>
    </p>
    <ul>
      <li><a href="/peptides/retatrutide-vs-tirzepatide" style="color: var(--primary);">Retatrutide vs Tirzepatide: Which Is Better for Weight Loss?</a></li>
      <li><a href="/peptides/retatrutide-cost" style="color: var(--primary);">How Much Will Retatrutide Cost? (Price Predictions)</a></li>
      <li><a href="/guides/tirzepatide-no-insurance" style="color: var(--primary);">How to Get Tirzepatide Without Insurance (2026)</a></li>
    </ul>

    <MedicalDisclaimer />
    <FAQSection faqs={faqs} />
  </div>

  <!-- Sticky CTA Bar -->
  <div style="position: fixed; bottom: 0; left: 0; right: 0; background: linear-gradient(135deg, #10b981 0%, #059669 100%); padding: 16px 24px; text-align: center; box-shadow: 0 -4px 12px rgba(0,0,0,0.1); z-index: 100;">
    <div style="max-width: 1200px; margin: 0 auto; display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px;">
      <div style="color: white; font-weight: 600; font-size: 1.05rem;">
        ‚ö° Can't wait for retatrutide? Start losing weight today with tirzepatide ($179/mo)
      </div>
      <a href={affiliateLinks.medvi} target="_blank" rel="noopener sponsored" style="background: white; color: #059669; padding: 12px 32px; border-radius: 8px; font-weight: 700; text-decoration: none; white-space: nowrap; transition: all 0.2s;">
        Start with MEDVi ‚Üí
      </a>
    </div>
  </div>
</BaseLayout>
